Bath & Body Works Inc. (NYSE: BBWI), a provider of personal care and home fragrance products, on Monday reported an increase in net sales for the third quarter of 2024.
- The company reported net sales of $1.61 billion for Q3, higher than the $1.56 billion reported in the year-ago quarter
- On an adjusted basis, third-quarter earnings per share increased to $0.49 from $0.48 in the same period of fiscal 2023
- Net income, including special items, came in at $106 million in the October quarter, compared to $119 million in the corresponding period last year
- On a per-share basis, reported earnings decreased to $0.49 in Q3 from $0.52 in the prior-year quarter
- For the fourth quarter, the company expects net sales to decline between 6.5% and 4.5%, compared to $2.91 billion last year
- Q4 earnings, on a per-share basis, are expected to be between $1.94 and $2.07, compared to $2.55 in the fourth quarter of 2023
- For fiscal 2024, the management expects net sales to decrease 2.5-1.7%, vs. $7.43 billion in fiscal 2023
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs
